FBB Biomed provides a Research Use Only (RUO) blood test powered by Personalized Genomic Intelligence for precision neurology research. This platform offers actionable insights to stratify patients with neurodegenerative diseases, enhancing medical and pharmaceutical research precision. The service allows research participants to gain novel insights into brain health without invasive procedures like a lumbar puncture.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IEFounders
Product
Problem
Current diagnostic methods for neurological disorders often rely on invasive procedures like spinal taps or only detect the disease after significant progression. This results in delayed diagnoses and limits opportunities for early intervention and treatment. Existing blood tests may also lack accuracy across diverse populations, leading to disparities in diagnosis.
Solution
FBB Biomed offers a blood-based test that analyzes viral and ancestral genetic elements to assess neurological health, providing a less invasive alternative to spinal taps. The research-use-only test uses advanced genomics and AI to identify biomarkers associated with various neurological conditions, including Alzheimer's, Parkinson's, and Multiple Sclerosis, as well as certain cancers and autoimmune diseases. By identifying disease-specific ancestral gene expression patterns, the test aims to improve disease substratification and enhance clinical trial precision. The test results provide an objective foundation for patient stratification in clinical trials, potentially de-risking trials and improving patient selection. The company collaborates with researchers and drug developers to advance biomarker-driven neuropsychiatric research.
Target Audience
The primary target audience includes clinical researchers, pharmaceutical companies, and medical professionals focused on neurology and related fields, as well as individuals participating in research programs.
Features
- Minimally invasive blood test for neurological health assessment
- Analysis of viral and ancestral genetic elements
- AI-driven analysis of gene expression patterns
- Identification of biomarkers associated with neurological conditions, cancers, and autoimmune diseases
- Disease substratification for enhanced clinical trial precision
- Detection of biomarkers associated with depression and schizophrenia
- RUO test designed to identify dementia in its earliest stages